Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,035,805
  • Shares Outstanding, K 395,302
  • Annual Sales, $ 614,060 K
  • Annual Income, $ -18,000 K
  • 60-Month Beta 2.23
  • Price/Sales 3.33
  • Price/Cash Flow N/A
  • Price/Book 3.24
Trade AMRN with:

Options Overview

Details
  • Implied Volatility 88.16%
  • Historical Volatility 32.98%
  • IV Percentile 67%
  • IV Rank 14.69%
  • IV High 302.18% on 02/25/21
  • IV Low 51.31% on 09/01/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 9,735
  • Volume Avg (30-Day) 6,174
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 153,423
  • Open Int (30-Day) 167,541

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.03
  • Number of Estimates 5
  • High Estimate 0.00
  • Low Estimate -0.05
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +2.28%
on 09/08/21
5.97 -13.74%
on 08/23/21
-0.46 (-8.20%)
since 08/17/21
3-Month
3.84 +34.29%
on 07/27/21
5.97 -13.74%
on 08/23/21
+0.22 (+4.46%)
since 06/17/21
52-Week
3.36 +53.27%
on 09/24/20
9.25 -44.32%
on 02/03/21
+0.95 (+22.62%)
since 09/17/20

Most Recent Stories

More News
4 Great Stocks Under $10 You Can Buy Right Now

The stock market is on a winning streak, with the benchmark S&P 500 index recording fresh highs for seven straight months. Given surging investor confidence and strong economic recovery, we think fundamentally...

WIT : 9.34 (-1.37%)
TKC : 4.58 (-0.65%)
AMRN : 5.15 (-0.39%)
LOMA : 7.27 (+0.41%)
October 8th Options Now Available For Amarin (AMRN)

Investors in Amarin Corp plc saw new options begin trading today, for the October 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options chain for the...

AMRN : 5.15 (-0.39%)
Amarin Reports Data from REDUCE-IT(R) Showing VASCEPA(R)/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction

AMRN : 5.15 (-0.39%)
Latest Clinical Research Evaluating VASCEPA(R)/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge on VASCEPA(R)/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular...

AMRN : 5.15 (-0.39%)
HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa® in Canada

COMTEX_391640062/2669/2021-08-16T06:30:29

HLS.TO : 18.24 (+0.94%)
AMRN : 5.15 (-0.39%)
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock...

RDY : 66.35 (-0.85%)
TEVA : 8.99 (+0.45%)
VRTX : 188.30 (+0.64%)
AMRN : 5.15 (-0.39%)
What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

SNY : 48.38 (+0.39%)
DVAX : 14.89 (+3.12%)
AMGN : 219.38 (+0.93%)
AMRN : 5.15 (-0.39%)
September 10th Options Now Available For Amarin

Investors in Amarin Corp plc saw new options begin trading today, for the September 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options chain for...

AMRN : 5.15 (-0.39%)
Interesting AMRN Put And Call Options For March 2022

Investors in Amarin Corp plc saw new options become available this week, for the March 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time...

AMRN : 5.15 (-0.39%)
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter and six month 2021 financial results...

AMRN : 5.15 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

3rd Resistance Point 5.36
2nd Resistance Point 5.28
1st Resistance Point 5.22
Last Price 5.15
1st Support Level 5.08
2nd Support Level 5.00
3rd Support Level 4.94

See More

52-Week High 9.25
Fibonacci 61.8% 7.00
Fibonacci 50% 6.30
Fibonacci 38.2% 5.61
Last Price 5.15
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar